Paul Claydon

Paul Claydon is a partner in Covington’s London office. He has more than 30 years’ experience in advising clients on mergers and acquisitions, IPOs and other securities issues, as well as corporate finance, private equity and venture capital transactions. His clients include corporates, private equity funds and investment banks.

Mr. Claydon’s practice covers a wide range of industries; he has particular expertise in advising on deals in the life sciences sector. He advised BioNTech on its $150 million initial public fundraising on NASDAQ, and on its recent $500 million follow-on offering. He has also advised Oxford Biomedica plc, ReNeuron Group plc, and QuantuMDx Group Ltd on recent fundraisings. Mr. Claydon has advised on many private and public M&A deals, and recently advised Horizon Discovery Group plc on its £300 million all cash recommended takeover by PerkinElmer, Inc., implemented via a court-approved Scheme of Arrangement. He regularly advises boards of directors on corporate governance and related issues.